Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/10/2003CA2190130C Thiadiazoles and their use as antipicornaviral agents
06/10/2003CA2189603C Propiophenone derivative and processes for preparing the same
06/10/2003CA2133427C Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders
06/10/2003CA2120020C Air treatment plant for foodstuff comprising a trough with an adjustable width
06/10/2003CA2093510C Oxysulfonyl carbamates
06/10/2003CA2083505C New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders
06/10/2003CA2072047C Pharmaceutical compositions
06/10/2003CA2065572C Novel complex phosphorous lipid based dietetic compositions and their use in sleep disorders
06/10/2003CA2055670C Retroviral protease inhibiting compounds
06/10/2003CA2054619C Aminocoumaran derivatives, their production and use
06/10/2003CA2040489C 4-¬3-(4-oxothiazoldinyl)|butynylamines, a process for their preparation and their use as medicaments
06/07/2003CA2412838A1 Filtering composition containing a dibenzoylmethane derived filter type and a 2-hydroxybenzophenone aminosubstituted derived filter type
06/07/2003CA2376719A1 A method to improve the safety of gene therapy
06/06/2003CA2436943A1 Hydantoin compounds useful as anti-inflammatory agents
06/06/2003CA2413479A1 Kit for reducing aching
06/05/2003WO2003046580A1 Assay for screening candidate drugs for the treatment of inflammatory diseases
06/05/2003WO2003046207A2 Methods for inhibiting deacetylase activity
06/05/2003WO2003046185A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
06/05/2003WO2003046181A1 Non-human transgenic mammals used as models for human pathologies originating from stem cells
06/05/2003WO2003046180A2 Human cdnas and proteins and uses thereof
06/05/2003WO2003046179A2 G-protein coupled receptor lustr2 and uses thereof
06/05/2003WO2003046171A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046170A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003045999A2 Human vanilloid receptor protein and polynucleotide sequence encoding same
06/05/2003WO2003045982A1 Antibiotics fki-9739 and process for producing the same
06/05/2003WO2003045977A2 Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
06/05/2003WO2003045973A2 Peptides with growth inhibitory action
06/05/2003WO2003045972A1 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17α-ALKYL-17β-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
06/05/2003WO2003045968A1 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
06/05/2003WO2003045967A1 Aryl fused azapolycyclic compounds
06/05/2003WO2003045965A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003WO2003045962A1 Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
06/05/2003WO2003045955A1 Use of selective potassium channel openers
06/05/2003WO2003045954A1 Use of selective potassium channel openers
06/05/2003WO2003045953A1 Crystals of taxane derivative and process for their production
06/05/2003WO2003045952A2 Condensed camptothecins as antitumor agents
06/05/2003WO2003045951A1 Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
06/05/2003WO2003045947A1 Rosiglitazone edisylates and their use as antidiabetics
06/05/2003WO2003045946A1 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
06/05/2003WO2003045945A1 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
06/05/2003WO2003045944A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
06/05/2003WO2003045940A2 Benzazepine derivatives and their use as 5-ht ligands
06/05/2003WO2003045939A1 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
06/05/2003WO2003045938A1 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23
06/05/2003WO2003045937A1 N-ureido-piperidines as antagonists viii for ccr-3 receptor
06/05/2003WO2003045929A1 Bicyclic derivative, process for producing the same, and use
06/05/2003WO2003045926A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003WO2003045925A1 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors
06/05/2003WO2003045923A1 Preventives or remedies for alzheimer’s disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
06/05/2003WO2003045922A1 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies
06/05/2003WO2003045921A1 Heterocyclic amide compounds as apolipoprotein b inhibitors
06/05/2003WO2003045920A1 4-aminoquinoline compounds
06/05/2003WO2003045918A1 Piperidine-based mch antagonists for treatment of obesity and cns disorders
06/05/2003WO2003045917A2 Ccr-3 receptor antagonists vii
06/05/2003WO2003045913A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use
06/05/2003WO2003045912A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
06/05/2003WO2003045910A2 Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
06/05/2003WO2003045908A2 Method for controlling angiogenesis in animals
06/05/2003WO2003045906A2 Synthesis of 2-cyanoziridine-1-carboxamide
06/05/2003WO2003045905A1 Hydroperylene derivatives
06/05/2003WO2003045903A1 Hydroxyethylene compounds with asp2 inhibitory activity
06/05/2003WO2003045902A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/05/2003WO2003045898A1 Prodrugs of excitatory amino acids
06/05/2003WO2003045896A1 New process
06/05/2003WO2003045893A1 Double esters
06/05/2003WO2003045582A1 Metallic structures incorporating bioactive materials and methods for creating the same
06/05/2003WO2003045523A2 Therapeutic coating for an intravascular implant
06/05/2003WO2003045494A2 Imiquimod therapies
06/05/2003WO2003045466A2 Catheter composition and uses thereof
06/05/2003WO2003045438A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue
06/05/2003WO2003045437A1 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
06/05/2003WO2003045435A1 Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
06/05/2003WO2003045434A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
06/05/2003WO2003045433A1 Remedies for heart failure
06/05/2003WO2003045432A1 Treatment of neovascular ophthalmic disease
06/05/2003WO2003045431A2 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
06/05/2003WO2003045429A2 Anti-t cell immunotoxin fusion protein and its therapeutic use
06/05/2003WO2003045420A2 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
06/05/2003WO2003045417A1 Antiglaucomatous agent and use thereof
06/05/2003WO2003045414A2 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
06/05/2003WO2003045411A2 Ginger extract preparation
06/05/2003WO2003045410A1 Pharmaceutical preparation containing micro-encapsulated or nano-encapsulated ginsenosides
06/05/2003WO2003045402A1 ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, AND REPTILES FROM (1-4) LINKED β-D-MANNURONIC ACID
06/05/2003WO2003045401A1 Compositions and methods for animal treatment
06/05/2003WO2003045400A1 Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
06/05/2003WO2003045399A2 Composition based on diosgenin ester for topical use
06/05/2003WO2003045397A1 Dosage regimen and pharmaceutical composition for emergency contraception
06/05/2003WO2003045396A1 Estrogen receptor beta-selective agonists for anti-catabolic therapy in an aging organism
06/05/2003WO2003045395A1 Quinazoline derivatives for the treatment of t cell mediated diseases
06/05/2003WO2003045394A1 Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
06/05/2003WO2003045393A1 Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
06/05/2003WO2003045392A2 Use of n-(indolcarbonyl-)piperazine derivatives
06/05/2003WO2003045391A1 Pharmaceutical formulations comprising an immune response modifier
06/05/2003WO2003045390A1 A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A β -LACTAM ANTIBIOTIC
06/05/2003WO2003045389A1 A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent
06/05/2003WO2003045388A1 Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
06/05/2003WO2003045387A1 Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative
06/05/2003WO2003045386A1 Benzothiazole derivatives
06/05/2003WO2003045385A1 Benzothiazole derivatives
06/05/2003WO2003045384A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases